Published in J Clin Neurol on September 20, 2006
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med (2006) 5.10
Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci (2001) 4.99
Pathogenesis of leukoaraiosis: a review. Stroke (1997) 4.95
The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A (1990) 4.46
Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci (2001) 3.71
Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke (1998) 3.58
Matrix metalloproteinases in neuroinflammation. Glia (2002) 3.51
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab (2000) 3.04
Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab (1999) 2.41
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 2.30
Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation (2003) 2.30
Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke (2006) 2.27
Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia (2005) 2.25
C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20
Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry (1997) 2.05
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 1.95
Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab (1999) 1.87
Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab (2001) 1.81
Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke (2004) 1.81
Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation (1995) 1.73
Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke (2001) 1.73
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 1.71
Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke (1995) 1.71
Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke (2001) 1.69
Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke (2001) 1.66
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke (2004) 1.63
Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab (1998) 1.63
White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke (2001) 1.59
Recovery recapitulates ontogeny. Trends Neurosci (2000) 1.59
Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport (2001) 1.53
Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett (1997) 1.49
The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci (1992) 1.48
Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res (2002) 1.42
Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery (1997) 1.36
Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab (2003) 1.28
Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke (1997) 1.18
The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and their relationship to age and clinical features. AJNR Am J Neuroradiol (2005) 1.15
Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J (2002) 1.15
Tissue plasminogen activator and NMDA receptor cleavage. Nat Med (2003) 1.14
Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int (2003) 1.13
Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis (2005) 1.09
Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol (2001) 1.07
Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci (2003) 1.05
Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery (2002) 1.02
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol (2000) 1.01
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J (2005) 1.00
Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett (2000) 0.99
Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis (2006) 0.98
Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest (2005) 0.98
Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2. Stroke (1998) 0.96
Leukoaraiosis and vascular dementia. Neurology (1998) 0.94
Remodeling after stroke. Nat Med (2006) 0.89
Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data. Eur J Vasc Endovasc Surg (2006) 0.85
Gelatinases [matrix metalloproteinase-2 (MMP-2) and MMP-9] induce carotid plaque instability but their systemic levels are not predictive of local events. Ann Vasc Surg (2005) 0.84
Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med (2006) 0.81
Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest (2004) 0.80
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease. Eur Neurol (2004) 0.78
Induced neurogenesis by endogenous progenitor cells in the adult mammalian brain. Prog Brain Res (2002) 0.78
Urine neural thread protein measurements in Alzheimer disease. J Am Med Dir Assoc (2010) 1.47
Male-specific alteration in excitatory post-synaptic development and social interaction in pre-natal valproic acid exposure model of autism spectrum disorder. J Neurochem (2013) 0.99
Alternations of Septal-hippocampal System in the Adult Wistar Rat with Spatial Memory Impairments Induced by Chronic Cerebral Hypoperfusion. Exp Neurobiol (2011) 0.98
Combined extracranial and intracranial atherosclerosis in Korean patients. Arch Neurol (2003) 0.96
Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J Pineal Res (2003) 0.94
Prenatal exposure to valproic acid increases the neural progenitor cell pool and induces macrocephaly in rat brain via a mechanism involving the GSK-3β/β-catenin pathway. Neuropharmacology (2012) 0.92
Differential cholinergic pathway involvement in Alzheimer's disease and subcortical ischemic vascular dementia. J Alzheimers Dis (2013) 0.89
Synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amlyloid toxicity in a rat model. Stroke (2011) 0.89
Voxel-based analysis of diffusion tensor imaging in patients with subcortical vascular cognitive impairment: correlates with cognitive and motor deficits. J Neuroimaging (2010) 0.88
Reversible antecollis associated with pramipexole in a patient with Parkinson's disease. J Clin Neurosci (2012) 0.88
Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J Pineal Res (2010) 0.87
Validation of the Literacy Independent Cognitive Assessment. Int Psychogeriatr (2010) 0.87
Effects of Fructus mume Extract on MAPK and NF-κB Signaling and the Resultant Improvement in the Cognitive Deficits Induced by Chronic Cerebral Hypoperfusion. Evid Based Complement Alternat Med (2012) 0.87
Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neurosci Lett (2009) 0.87
A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy. Clin Neurol Neurosurg (2005) 0.87
Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J Neurochem (2012) 0.87
Neuroprotective effects of valproic acid against hemin toxicity: possible involvement of the down-regulation of heme oxygenase-1 by regulating ubiquitin-proteasomal pathway. Neurochem Int (2013) 0.86
Dexibuprofen (S(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion. Pharmacol Biochem Behav (2008) 0.84
Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol (2010) 0.84
Effects of education on the progression of early- versus late-stage mild cognitive impairment. Int Psychogeriatr (2012) 0.84
Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid. Food Chem Toxicol (2012) 0.84
Terminal changes in hereditary sensory and autonomic neuropathy: a long-term follow-up of a sporadic case. Clin Neurol Neurosurg (2003) 0.84
Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1. Neurochem Int (2010) 0.83
Effects of Scutellaria baicalensis on chronic cerebral hypoperfusion-induced memory impairments and chronic lipopolysaccharide infusion-induced memory impairments. J Ethnopharmacol (2011) 0.83
Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes. Neurochem Res (2008) 0.83
NADPH oxidase 1, a novel molecular source of ROS in hippocampal neuronal death in vascular dementia. Antioxid Redox Signal (2014) 0.83
Prenatal exposure of ethanol induces increased glutamatergic neuronal differentiation of neural progenitor cells. J Biomed Sci (2010) 0.83
Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes. Nitric Oxide (2009) 0.83
Validation of the Korean version of the Bayer activities of daily living scale. Hum Psychopharmacol (2003) 0.82
Differences in hippocampal CREB phosphorylation in trace fear conditioning of two inbred mouse strains. Brain Res (2010) 0.82
Isolated oculomotor nerve palsy: diagnostic approach using the degree of external and internal dysfunction. Clin Neurol Neurosurg (2002) 0.82
Macelignan attenuates activations of mitogen-activated protein kinases and nuclear factor kappa B induced by lipopolysaccharide in microglial cells. Biol Pharm Bull (2009) 0.82
Activation of microglial cells via protease-activated receptor 2 mediates neuronal cell death in cultured rat primary neuron. Nitric Oxide (2009) 0.82
Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: A five-year longitudinal study. Dement Geriatr Cogn Disord (2010) 0.81
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem (2013) 0.81
Effect of 710-nm visible light irradiation on neuroprotection and immune function after stroke. Neuroimmunomodulation (2012) 0.81
Chronic exposure to ethanol of male mice before mating produces attention deficit hyperactivity disorder-like phenotype along with epigenetic dysregulation of dopamine transporter expression in mouse offspring. J Neurosci Res (2014) 0.81
Fluid-attenuated inversion recovery hypointensity of the pulvinar nucleus of patients with Alzheimer disease: its possible association with iron accumulation as evidenced by the t2(*) map. Korean J Radiol (2012) 0.81
Clinical characteristics of a nationwide hospital-based registry of mild-to-moderate Alzheimer's disease patients in Korea: a CREDOS (Clinical Research Center for Dementia of South Korea) study. J Korean Med Sci (2011) 0.81
Validity and reliability of the Korean version of the AD8 informant interview (K-AD8) in dementia. Alzheimer Dis Assoc Disord (2009) 0.80
Reliability and validity of the short form of the literacy-independent cognitive assessment in the elderly. J Clin Neurol (2013) 0.80
Effects of ethanol exposure during early pregnancy in hyperactive, inattentive and impulsive behaviors and MeCP2 expression in rodent offspring. Neurochem Res (2013) 0.80
Effects of Korean Red Ginseng extract on tissue plasminogen activator and plasminogen activator inhibitor-1 expression in cultured rat primary astrocytes. J Ginseng Res (2013) 0.80
A role of CPEB1 in the modulation of proliferation and neuronal maturation of rat primary neural progenitor cells. Neurochem Res (2013) 0.79
The effect of ischemic cholinergic damage on cognition in patients with subcortical vascular cognitive impairment. J Geriatr Psychiatry Neurol (2012) 0.79
Regional atrophy of the insular cortex is associated with neuropsychiatric symptoms in Alzheimer's disease patients. Eur Neurol (2014) 0.79
Activation of adenosine A2A receptor up-regulates BDNF expression in rat primary cortical neurons. Neurochem Res (2011) 0.79
Neuropsychological correlates of the proportional impact of white matter hyperintensities on mild to moderate dementia: the MRI 300 study. Dement Geriatr Cogn Disord (2011) 0.79
Transient global amnesia following vertebral artery angioplasty and stenting. Eur Neurol (2006) 0.79
Effect of HDAC inhibitors on neuroprotection and neurite outgrowth in primary rat cortical neurons following ischemic insult. Neurochem Res (2013) 0.79
tPA regulates neurite outgrowth by phosphorylation of LRP5/6 in neural progenitor cells. Mol Neurobiol (2013) 0.78
Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9. Neurochem Res (2010) 0.78
Neuropsychiatric predictors of conversion to dementia both in patients with amnestic mild cognitive impairment and those with subcortical vascular MCI. Clin Neurol Neurosurg (2013) 0.78
Valproic Acid Regulates α-Synuclein Expression through JNK Pathway in Rat Primary Astrocytes. Biomol Ther (Seoul) (2013) 0.78
Pyramidal and extrapyramidal scale (PEPS): a new scale for the assessment of motor impairment in vascular cognitive impairment associated with small vessel disease. Clin Neurol Neurosurg (2010) 0.78
A simple behavioral paradigm to measure impulsive behavior in an animal model of attention deficit hyperactivity disorder (ADHD) of the spontaneously hypertensive rats. Biomol Ther (Seoul) (2012) 0.77
Depressive-like behaviors in a rat model of chronic cerebral hypoperfusion. Transl Stroke Res (2014) 0.77
Neurologic signs in relation to cognitive function in subcortical ischemic vascular dementia: a CREDOS (Clinical Research Center for Dementia of South Korea) study. Neurol Sci (2011) 0.77
Clinical and Neuropsychological Comparisons of Early-Onset Versus Late-Onset Frontotemporal Dementia: A CREDOS-FTD Study. J Alzheimers Dis (2015) 0.76
Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial. Psychother Psychosom (2016) 0.76
Validation analysis of the Attention Questionnaire Scale. J Alzheimers Dis (2011) 0.76
Resveratrol down-regulates a glutamate-induced tissue plasminogen activator via Erk and AMPK/mTOR pathways in rat primary cortical neurons. Food Funct (2014) 0.76
Glucose deprivation reversibly down-regulates tissue plasminogen activator via proteasomal degradation in rat primary astrocytes. Life Sci (2013) 0.76
Pure word deafness in a patient with early-onset Alzheimer's disease: an unusual presentation. J Clin Neurol (2011) 0.75
An acute tiny left putamenal lesion presenting with transient global amnesia. Neurologist (2012) 0.75
Vascular factors are associated with the severity of the neuropsychiatric symptoms in Alzheimer's disease. Int J Neurosci (2013) 0.75
Oroxylin A Induces BDNF Expression on Cortical Neurons through Adenosine A2A Receptor Stimulation: A Possible Role in Neuroprotection. Biomol Ther (Seoul) (2012) 0.75
Association between functional impairment, depression, and extrapyramidal signs in neuroleptic-free patients with Alzheimer disease. J Geriatr Psychiatry Neurol (2013) 0.75
Proteinase 3 induces oxidative stress-mediated neuronal death in rat primary cortical neuron. Neurosci Lett (2013) 0.75
Ginkgo biloba extract (Egb761) attenuates zinc-induced tau phosphorylation at Ser262 by regulating GSK3β activity in rat primary cortical neurons. Food Funct (2015) 0.75
Validation of the Korean version of the Syndrom Kurztest (SKT): a short test for the assessment of memory and attention. Hum Psychopharmacol (2004) 0.75
Regulation of tissue plasminogen activator/plasminogen activator inhibitor-1 by hydrocortisone in rat primary astrocytes. J Neurosci Res (2011) 0.75